Table 3.

Reporting of systemic adverse reactions in the 7 days after the first and second vaccine dose administration, stratified by symptom severity.

	Dose 1	Dose 2
	N = 296	N = 275
Fever, n (% and 95%CI)
Any	15 (5.1%, 95%CI 2.9–8.2)	85 (30.9%, 95%CI 25.5–36.7)
≥37.5 °C to 38.0 °C	12 (4.1%, 95%CI 2.1–7.0)	58 (21.1%, 95%CI 16.4–26.4)
>38.0 °C to 38.5 °C	3 (1.0%, 95%CI 0.2–2.9)	18 (6.6%, 95%CI 3.9–10.2)
>38.5 °C to 39.0 °C	0 (0)	8 (2.9%, 95%CI 1.3–5.7)
>39.0 °C to 40.0 °C	0 (0)	1 (0.4%, 95%CI 0.0–2.0)
>40.0 °C	0 (0)	0 (0)
Fatigue, n (% and 95%CI)
Any	126 (42.6%, 95%CI 36.9–48.4)	206 (74.9%, 95%CI 69.4–79.9)
Mild	85 (28.7%, 95%CI 23.6–34.2)	82 (29.8%, 95%CI 24.5–35.6)
Moderate	41 (13.9%, 95%CI 10.1–18.3)	107 (38.9%, 95%CI 33.1–45.0)
Severe	0 (0)	17 (6.2%, 95%CI 3.6–9.7)
Grade 4	0 (0)	0 (0)
Headache, n (% and 95%CI)
Any	100 (33.8%, 95%CI 28.4–39.5)	158 (57.5%, 95%CI 51.4–63.4)
Mild	56 (18.9%, 95%CI 14.6–23.9)	77 (28.0%, 95%CI 22.8–33.7)
Moderate	40 (13.5%, 95%CI 9.8–17.9)	68 (24.7%, 95%CI 19.7–30.3)
Severe	4 (1.4%, 95%CI 0.4–3.4)	13 (4.7%, 95%CI 2.5–8.0)
Grade 4	0 (0)	0 (0)
Gastrointestinal symptoms, n (% and 95%CI)
Any	17 (5.7%, 95%CI 3.4–9.0)	40 (14.5%, 95%CI 10.6–19.3)
Mild	17 (5.7%, 95%CI 3.4–9.0)	37 (13.5%, 95%CI 9.7–18.1)
Moderate	0 (0)	3 (1.1%, 95%CI 0.2–3.2)
Severe	0 (0)	0 (0)
Grade 4	0 (0)	0 (0)
Muscle/Joint pain, n (% and 95%CI)
Any	83 (28.0%, 95%CI 23.0–33.5)	160 (58.2%, 95%CI 52.1–64.1)
Mild	56 (18.9%, 95%CI 14.6–23.9)	72 (26.2%, 95%CI 21.1–31.8)
Moderate	25 (8.5%, 95%CI 5.5–12.2)	77 (28.0%, 95%CI 22.8–33.7)
Severe	2 (0.7%, 95%CI 0.1–2.4)	11 (4.0%, 95%CI 2.0–7.0)
Grade 4	0 (0)	0 (0)
Chills, n (% and 95%CI)
Any	35 (11.8%, 95%CI 8.4–16.1)	105 (38.2%, 95%CI 32.4–44.2)
Lymph node enlargement, n (% and 95%CI)
Any	35 (11.8%, 95%CI 8.4–16.1)	50 (18.2%, 95%CI 13.8–23.3)
Neurological symptoms, n (% and 95%CI)
Any	2 (0.7%, 95%CI 0.1–2.4)	6 (2.2%, 95%CI 0.8–4.7)